ArticlePloS one2025
Propagation of antibacterial cold atmospheric pressure plasma through small-bore tubing.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cold atmospheric pressure plasma (CAPP) is well documented to have microbicidal properties including against non-pathogenic Escherichia coli. In this feasibility study, a semi-quantitative method was developed to measure bactericidal activity of argon-CAPP (Ar-CAPP). Ar-CAPP susceptibility then was tested for a variety of clinically relevant E. coli strains, both uropathogenic E. coli (UPEC) and strains resistant to multiple antibiotics. All strains tested were found similarly susceptible to the antibacterial effects of Ar-CAPP. Next, methods were developed to propagate Ar-CAPP through defined lengths of plastic tubing with internal diameters ranging from 0.8 to 3.5 mm. Ar-CAPP propagated throughout all sizes of tubing tested, with visible plasma plumes exiting from the distal ends of the tubing. Bactericidal effects of the plasma efflux were tested against E. coli. Only partial loss of bactericidal activity was seen in tubing efflux plasma compared to control plasma jet plume unobstructed by tubing. Future work will develop bacterial biofilms on the internal surfaces of tubing to determine whether Ar-CAPP will ablate biofilms or kill biofilm bacteria. If successful, Ar-CAPP could further be tested for feasibility of disinfection of urinary catheters and other re-useable insertable medical devices in at-home and hospital settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.